Contineum director granted 19,000 stock options
Contineum Therapeutics, Inc. director Sarah Boyce received a grant of stock options covering 19,000 shares of Class A common stock.
Rhea-AI Filing Summary
Contineum Therapeutics, Inc. director Sarah Boyce received a grant of stock options covering 19,000 shares of Class A common stock. The options have an exercise price of $14.19 per share and were issued under the company’s 2024 Equity Incentive Plan as part of its Non-Employee Director Compensation Program.
According to the terms, the options will vest in full on the earlier of June 26, 2027, or the next regular annual meeting of stockholders, provided she continues to serve as a director. This is a routine compensation-related award and does not involve any open-market buying or selling of shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 19,000 shares
Grant/Award
1 txn
Insider
Boyce Sarah
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 19,000 contracts (Direct)
Footnotes (1)
- F1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Key Figures
Option grant size: 19,000 options
Exercise price: $14.19 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Option grant size
19,000 options
Stock options for Class A common stock granted to director
Exercise price
$14.19 per share
Conversion/exercise price of granted stock options
Expiration date
June 25, 2036
Expiration of stock options granted to Sarah Boyce
Underlying shares
19,000 shares
Class A common stock underlying the option award
Vesting date reference
June 26, 2027
One-year anniversary of grant; earlier vesting if next annual meeting occurs first
Key Terms
2024 Equity Incentive Plan, Non-Employee Director Compensation Program, stock option, Class A Common Stock
4 terms
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"),"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended,"
stock option financial
"will automatically be granted a stock option under the Plan for 19,000 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Class A Common Stock financial
"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock."
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Contineum Therapeutics (CTNM) disclose about Sarah Boyce in this Form 4?
Contineum Therapeutics reported that director Sarah Boyce received a grant of stock options for 19,000 shares of Class A common stock at a $14.19 exercise price as part of the 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program.
How many Contineum Therapeutics (CTNM) options did Sarah Boyce receive and at what price?
Sarah Boyce was granted options to acquire 19,000 shares of Contineum Therapeutics Class A common stock. These options carry an exercise price of $14.19 per share and represent compensation awarded under the company’s 2024 Equity Incentive Plan for non-employee directors.
When do Sarah Boyce’s Contineum Therapeutics (CTNM) stock options vest?
The stock options granted to Sarah Boyce vest in full on the earlier of June 26, 2027, the one-year anniversary of the grant date, or the next regular annual meeting of stockholders, assuming she continues to serve as a member of the Board of Directors.
Is Sarah Boyce’s Contineum Therapeutics (CTNM) Form 4 transaction an open-market trade?
No, the Form 4 reports a compensation-related grant of stock options, not an open-market trade. The 19,000 options were awarded under the 2024 Equity Incentive Plan and Non-Employee Director Compensation Program, so no shares were bought or sold on the open market.
Under what plan were Sarah Boyce’s Contineum Therapeutics (CTNM) options granted?
The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan. They were issued pursuant to the company’s Non-Employee Director Compensation Program, which provides that each continuing non-employee director receives an automatic annual stock option grant after each regular stockholder meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
